Prospera Financial Services Inc cut its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,747 shares of the biopharmaceutical company’s stock after selling 785 shares during the period. Bristol-Myers Squibb comprises 0.6% of Prospera Financial Services Inc’s investment portfolio, making the stock its 22nd largest position. Prospera Financial Services Inc’s holdings in Bristol-Myers Squibb were worth $3,591,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Sowell Financial Services LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $212,000. Norges Bank acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $770,318,000. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $484,000. Vident Investment Advisory LLC boosted its position in shares of Bristol-Myers Squibb by 28.7% in the fourth quarter. Vident Investment Advisory LLC now owns 12,660 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 2,823 shares during the period. Finally, Access Financial Services Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $248,000. Hedge funds and other institutional investors own 69.79% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) traded down 0.85% during mid-day trading on Thursday, hitting $56.91. 2,311,153 shares of the stock traded hands. The stock has a 50-day moving average of $55.81 and a 200 day moving average of $54.58. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $61.30. The stock has a market cap of $93.33 billion, a PE ratio of 20.79 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the business posted $0.69 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. Equities analysts predict that Bristol-Myers Squibb Company will post $2.97 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.72%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
ILLEGAL ACTIVITY WARNING: “Prospera Financial Services Inc Reduces Position in Bristol-Myers Squibb Company (BMY)” was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2800706/prospera-financial-services-inc-reduces-position-in-bristol-myers-squibb-company-bmy.html.
A number of research analysts recently weighed in on BMY shares. BMO Capital Markets restated a “market perform” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Sunday, April 23rd. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $59.88 price objective for the company. in a report on Monday, April 24th. Robert W. Baird started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 25th. They issued an “outperform” rating for the company. Jefferies Group LLC restated a “buy” rating and issued a $64.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Finally, BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $62.67.
In other news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.